OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
A phase 3 trial of Fulvestrant and Exemestane in HR-positive / HER2-negative breast cancer, run by Olema Pharmaceuticals, Inc., active and no longer recruiting.
Overview
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer is a phase 3 interventional study registered as NCT06016738 by Olema Pharmaceuticals, Inc., with 510 participants enrolled, started 2023-11-16 and due to reach its primary completion in 2026-10-31. Interventions recorded: Palazestrant, Fulvestrant, Anastrozole, Letrozole and Exemestane.
Similar pages
not linked directly; found by shared links- TrialPalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Shares Olema Pharmaceuticals, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Shares Exemestane, Fulvestrant and the tag pipeline.
- TrialComparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Shares Exemestane, Fulvestrant and the tag pipeline.
- TrialEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Shares Exemestane, Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Fulvestrant, HR-positive / HER2-negative breast cancer and the tag pipeline.